Overview

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

Status:
Completed

Trial end date:
2020-09-23

Target enrollment:

Participant gender:

Summary

The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following oral administration.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Dabigatran
Rosuvastatin Calcium